Amarin Corp Plc (AMRN)

[HinduKush]

JL Thank you
As ever, you make several good points, the commoditization of V and the cost of production of GenV will be the key. In a Gen L vs. Gen V encounter, Gen L wins on both cost and established ease of prescription substitution. Winning a Gen L vs. "Vascepa Cardiac" encounter will have better chances as we are now distinguished by R-IT indication and are chemically different in constitution. I wish every bottle of fish oil, Lovaza and less than 96% pure EPA pills, could carry a government health (black box) warning: "Taking DHA has NOT been proven to improve cardiovascular health and may also be deleterious."
HK